All In Biotech

Drug Trial Radar · NCT00451451

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jan 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,417 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,417

Actual

Start

Jun 2007

Primary completion

Aug 2011

Study completion Aug 2011

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Mar 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse. Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • BG00012Drug

  • PlaceboDrug

  • Glatiramer AcetateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse RateTime frame: 2 years

Locations

195 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Cullman, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    La Jolla, California

  • Research Site

    Loma Linda, California

  • Research Site

    Pasadena, California

  • Research Site

    Sacramento, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Boulder, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Fort Collins, Colorado

  • Research Site

    Maitland, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Naples, Florida

  • Research Site

    Pompano Beach, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    Columbus, Georgia

  • Research Site

    Meridan, Idaho

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Kansas City, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Clinton Township, Michigan

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Dover, New Hampshire

  • Research Site

    Lebanon, New Hampshire

  • Research Site

    Freehold, New Jersey

  • Research Site

    Teaneck, New Jersey

  • Research Site

    Amherst, New York

  • Research Site

    Buffalo, New York

  • Research Site

    Cedarhurst, New York

  • Research Site

    Mineola, New York

  • Research Site

    Patchogue, New York

Showing 40 of 195 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.